Influenza vaccine immune response in patients with high-risk cardiovascular disease

JAMA Cardiology

2024-04-07

(Press-News.org) About The Study: High-dose influenza vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED randomized clinical trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality. Vaccination to prevent influenza remains critical in high-risk populations.

Authors: Scott D. Solomon, M.D., of Brigham and Women’s Hospital and Harvard Medical School in Boston, and Orly Vardeny, Pharm.D., M.S., of the University of Minnesota in Minneapolis, are the corresponding authors.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamacardio.2024.0468)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

# # #

Media advisory: This study is being released to coincide with presentation at the American College of Cardiology’s Annual Scientific Session.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.0468?guestAccessKey=69f06239-d636-4ea3-8197-2a0166603e1b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=040724

END

ELSE PRESS RELEASES FROM THIS DATE:

Plozasiran (ARO-APOC3) for severe hypertriglyceridemia

2024-04-07

About The Study: This randomized clinical trial demonstrates the potential clinical utility of plozasiran, an investigational APOC3-targeted small interfering–RNA drug, to reduce triglyceride level in patients with severe hypertriglyceridemia. Additional studies will be required to determine whether plozasiran favorably modulates the risk of severe hypertriglyceridemia-associated complications. Authors: Daniel Gaudet, M.D., Ph.D., of the Université de Montréal, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamacardio.2024.0959) Editor’s ...

Experimental drug could further reduce lipids in the blood in high-risk patients

2024-04-07

Hypertriglyceridemia, or high levels of lipids (fats) in the blood, increases the risk of heart attack, stroke and acute pancreatitis. Currently available medications, including statins, ezetimibe, fibrates and prescription omega 3 fatty acids, typically lower triglyceride levels by anywhere from below 10% to up to 40%. These therapies help, but they are not enough to prevent cardiovascular events in everyone. An experimental treatment could further lower triglycerides in the blood, according to a placebo-controlled ...

New evidence links passive smoking with dangerous heart rhythm disorder

2024-04-07

Berlin, Germany – 7 April 2024: Exposure to secondhand smoke – even at small amounts – is linked with greater risk of a serious heart rhythm disorder, according to research presented at EHRA 2024, a scientific congress of the European Society of Cardiology (ESC).1 The likelihood of atrial fibrillation increased as the duration of passive smoking lengthened. “The dangers of secondhand smoke were significant regardless of whether individuals were at home, outdoors, or at work, indicating that exposure universally elevates the risk of atrial ...

Oral vaccine for UTI is potential alternative to antibiotics, finds 9-year study

2024-04-07

Recurrent Urinary Tract Infections (UTIs) can be prevented for up to nine years in more than half of people given an oral spray-based vaccine and is a potential alternative to antibiotic treatments, finds research. Initial results from the first long-term follow-up study of the safety and effectiveness of the MV140 vaccine for recurrent UTIs are presented this weekend at the European Association of Urology (EAU) Congress in Paris. They show that in both men and women with recurrent UTIs, 54% of study participants remained UTI-free for nine years after the vaccine, with no notable side effects reported. Full results of the study are expected to be published ...

Antibiotic prophylaxis and infective endocarditis incidence following invasive dental procedures

2024-04-06

About The Study: This systematic review and meta-analysis including data on 1.1 million cases of infective endocarditis found that antibiotic prophylaxis was associated with a reduced risk of infective endocarditis following invasive dental procedures in individuals at high risk but not in those at moderate or low/unknown risk. Currently, there is insufficient data to support any benefit of antibiotic prophylaxis in individuals at moderate risk. Authors: Federica Turati, Ph.D., of the ...

A multimodal video-based AI biomarker for aortic stenosis development and progression

2024-04-06

About The Study: In this cohort study of patients without severe aortic stenosis undergoing echocardiography or cardiac magnetic resonance imaging, a new artificial intelligence (AI)-based video biomarker was independently associated with aortic stenosis development and progression, enabling opportunistic risk stratification across cardiovascular imaging modalities as well as potential application on handheld devices. Authors: Rohan Khera, M.D., M.S., of the Yale School of Medicine in New Haven, Connecticut, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamacardio.2024.0595) Editor’s ...

Inter-atrial shunts may benefit some heart failure patients while harming others

2024-04-06

Inter-atrial shunts—investigational devices that create a small pathway for blood to pass from the left to the right side of the heart in order to improve heart failure symptoms and outcomes—may be beneficial to heart failure patients with reduced left ventricular ejection fraction (LVEF) but harmful or even deadly for heart failure patients with preserved LVEF, a new Mount Sinai-led study shows. The findings of the RELIEVE-HF trial were announced during the opening late-breaking trial session at the American College of Cardiology Scientific Sessions on Saturday, April 6. This is the first study ...

Prostate cancer screening with PSA, Kallikrein Panel, and MRI

2024-04-06

About The Study: In this preliminary descriptive report from an ongoing randomized clinical trial, one additional high-grade cancer per 196 men and one low-grade cancer per 909 men were detected among those randomized to be invited to undergo a single prostate cancer screening intervention compared with those not invited to undergo screening. These preliminary findings from a single round of screening should be interpreted cautiously, pending results of the study’s primary mortality outcome. Authors: Anssi ...

PSA screening and 15-year prostate cancer mortality

2024-04-06

About The Study: A single invitation for prostate-specific antigen (PSA) screening compared with standard practice without routine screening reduced prostate cancer deaths at a median follow-up of 15 years in this secondary analysis of a randomized clinical trial. However, the absolute reduction in deaths was small. Authors: Richard M. Martin, B.M., B.S., Ph.D., of the University of Bristol in Bristol, United Kingdom, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jama.2024.4011) Editor’s ...

Screening with a PSA test has a small impact on prostate cancer deaths but leads to overdiagnosis

2024-04-06

The largest study to date investigating a single invitation to a PSA blood test* to screen for prostate cancer has found it had a small impact on reducing deaths, but also led to overdiagnosis and missed early detection of some aggressive cancers. The CAP trial, published in the Journal of the American Medical Association (JAMA) and carried out by researchers from the universities of Bristol, Oxford and Cambridge, involved over 400,000 men aged 50-69. Just under half received a single invitation for a PSA test as part of the trial. After following up for 15 years, there was a small difference in the number of men who died from prostate cancer between the ...

Korea University College of Medicine successfully concludes the 2025 Lee Jong-Wook Fellowship on Infectious Disease Specialists Program

Girls are happiest at school – for good reasons

Researchers from the University of Maryland School of Medicine discover genetic ancestry is a critical component of assessing head and neck cancerous tumors

Heart damage is common after an operation and often goes unnoticed, but patients who see a cardiologist may be less likely to die or suffer heart disease as a result

Influenza vaccine immune response in patients with high-risk cardiovascular disease

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: